Small Company Champion & Lemming Investors Research and Newsletter Updates

Friday, 11 December 2020

SkinBioTherapeutics - Chinese Feature

Breaking through the regulatory dilemma, the skin bacteria company has its own tricks

Editor's note:

With lifestyle changes, environmental changes, more and more modern people began to suffer from acne, eczema, psoriasis, skin allergies, dry skin and other skin problems. However, these problems are rare among indigenous peoples, such as hunter-gatherers and Amerindians in Africa. A growing body of research suggests that changes in the skin microbiome may have contributed to the emergence of skin diseases. And regulating skin microorganisms will have the opportunity to improve our skin health.

Today, we'll introduce SkinBioTherapeutics, a skin microbiome company. The company uses skin probiotic extracts to improve skin health. It is hoped that this article can bring some inspiration and help to the relevant industry people and readers.
SkinBio Therapeutics, Inc

We've all heard of probiotics, which have been shown to help heal wounds, prevent infections and enhance intestinal barrier function.

Although most people already know the importance of having a healthy gut microbiome, the effects of these "good" bacteria do not end up in our guts, where microbes perform just as important activities on the surface of the skin.

However, the benefits of probiotics or beneficial bacteria on the skin are not yet well understood by the public. But this is a promising direction: according to Fortune Business Insights, the global probiotic market will reach $74.7 billion by the end of 2025, and skin probiotics will be the driving force of this growth.

Not only are traditional cosmetics companies targeting skin microbes, but several start-ups have emerged.

SkinBioTherapeutics (LON: SBTX) has begun researching microorganisms that live on the surface of the skin to make it feel and look better. The life sciences company was separated from OptiBiotix Health (LON: OPTI) in 2015, although OptiBiotix remains a major shareholder with a 29.8% stake.

SkinBioTherapeutics, a life sciences company focused on skin health, has patented its proprietary technology SkinBiotix from research by Cathrine O'Neill and Andrew McBain of the University of Manchester.

In 2017, the University of Manchester-based spin-off made its debut at AIM, the London Stock Exchange's market for small growth companies, and successfully raised 4.5 million pounds (approximately RMB39.23 million) to continue developing the company's SkinBiotix technology and accelerate its clinical development.

In 2020, SkinBioTherapeutics announced an investment of 4 million pounds (approximately RMB34.87 million) to expand SkinBiotix technology in the oral and healthcare sectors.

SkinBiotix technology

Due to copyright laws, I incorporate a link to the source. You will need to open in a browser capable of translating Chinese to English. Access the article here.